Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a Phase 2 clinical-stage biopharmaceutical company focused on personalized oncology through the development of stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor, and its proprietary DRP® companion diagnostic platform. The Allarity news feed highlights how the company advances this program in advanced ovarian cancer and other hard-to-treat malignancies.
News updates commonly cover clinical trial milestones, such as enrollment progress and new Phase 2 data in platinum-resistant or platinum-ineligible ovarian cancer, including Kaplan–Meier analyses of overall survival and durability of response. Releases also report on regulatory developments, notably the FDA Fast Track designation granted to stenoparib for advanced ovarian cancer, and on scientific presentations at meetings like the AACR Special Conference on Ovarian Cancer and Biomarkers & Precision Medicine.
Investors and observers will find coverage of corporate and financial updates, including quarterly results, capital structure actions, and private placement transactions disclosed via Form 8-K. Additional news items describe the expansion of Allarity’s DRP® platform through licensing and laboratory services agreements with EU-based biotechnology partners, patent developments such as Australian acceptance for the stenoparib DRP®, and collaborations with institutions like the Indiana Biosciences Research Institute.
This page aggregates these announcements so readers can follow how Allarity is progressing stenoparib in ovarian cancer, preparing combination studies in recurrent small cell lung cancer, and broadening the use of its DRP® technology across oncology. For ongoing insight into trial data, regulatory interactions, intellectual property, and financing events related to ALLR, this curated news stream provides a centralized view.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Allarity Therapeutics, Inc. (Nasdaq: ALLR) has priced a public offering to raise approximately $7.5 million through the sale of 2,869,330 shares of common stock, 7,130,670 pre-funded warrants, and 10 million common warrants. The combined price is set at $0.75 per share and common warrant, with warrants having an exercise price of $0.85 per share and a five-year expiration.
The closing is anticipated around April 21, 2023, subject to customary conditions. Funds will be used for accounts payable, accrued liabilities, and general corporate purposes, including redeeming series A preferred stock.
A.G.P./Alliance Global Partners is the sole placement agent for this offering. The securities are offered under a registration statement effective as of April 18, 2023.
Allarity Therapeutics (NASDAQ:ALLR) has initiated Phase 1b of its clinical trial, dosing the first patient to assess the combination therapy of stenoparib and dovitinib for advanced solid tumors, particularly ovarian cancer.
Ovarian cancer remains a critical health issue, affecting 1 in 78 women, with over 19,000 diagnoses expected in 2023. The ovarian cancer treatment market is projected to grow from $3.2 billion in 2022 to $6.36 billion by 2027.
The trial aims to determine the maximum tolerated doses of both drugs and evaluate their combined therapeutic potential. Notably, this therapy could provide a promising alternative to traditional chemotherapy, addressing a significant need in cancer treatment.
Allarity Therapeutics announced that an abstract on the company's proprietary DRP® Companion Diagnostic for cisplatin has been accepted for a poster presentation at the 2023 ASCO Annual Meeting. The presentation will detail findings from a Phase 2 Clinical Study evaluating the diagnostic's utility in identifying metastatic breast cancer patients likely to respond to treatment with LiPlaCis®. This study was conducted in collaboration with hospitals in Denmark and aims to enhance personalized cancer treatment. The poster will be featured on June 3, 2023, and the data highlights the DRP® platform's predictive capabilities, which have been validated in numerous clinical studies. Allarity continues to work on its drug candidates, including stenoparib and IXEMPRA®, while maintaining a focus on innovative cancer therapies.
Allarity Therapeutics (NASDAQ: ALLR) announced updates regarding its phase 2 clinical trials for IXEMPRA® and stenoparib. Efforts to enhance patient recruitment are a priority to meet the interim data readouts expected by the end of 2023. Recruitment has faced delays due to COVID-19, prompting Allarity to collaborate with multiple contract research organizations and amend trial protocols to broaden eligibility. For IXEMPRA, the DRP companion diagnostic cut-off score has been lowered from 67% to 33% to improve patient enrollment. For stenoparib, dosing will shift to a twice-daily regimen.